8 Things Most Americans Dont Know About Retirement
Comments Flood In on DOL Fiduciary Rule Delay
Betterment Rebuffs Buffett, Says Sages Advice Doesnt Work Anymore
Developing the next generation of talent and worries over cybersecurity are the top priorities for RIAs, according to a just-released Investment Adviser Association and Cerulli Associates poll.
In the premier 2017 Executive Outlook Survey – the first in an annual series of surveys measuring and tracking business sentiment among IAA member executives – 63% of firms polled said they plan to grow their workforces over the next 12 months. More than half (56%) plan to grow by up to 10%, while 7% said they plan to increase their staffs by more than 10%.
Financial firms will increasingly adopt blockchain technology in the post-trade space over the next three to five years, according to…
You are signed up!
ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources STRAIGHT-THROUGH PROCESSING FOR THE FINANCIAL SERVICES INDUSTRY
STP can be described as electronically capturing and processing transactions in one pass, from the point of first ‘deal’ to final settlement.
what is an investment: AbbVie Inc.(ABBV)
- [By Keith Speights]
Smart investors will be ready to take advantage of a market pullback, whenever it comes and offers discount prices on great stocks. Three drug stocks appear to be excellent choices to buy on a dip: AbbVie (NYSE:ABBV), Allergan (NYSE:AGN), and Celgene (NASDAQ:CELG). Here’s why.
- [By George Budwell]
If you’ve been following this stock for any length of time, you’re probably painfully aware that Gilead’s hep C franchise sank like a stone last year. The short version of the story is that the biotech’s super-aggressive pricing strategy for Sovaldi and Harvoni sowed discontent among payers, leading to a pricing war once rival drugs like AbbVie’s (NYSE:ABBV) Viekira Pak hit the market.
- [By Todd Campbell]
AbbVie, Inc.(NYSE:ABBV) is already awaiting a Food and Drug Administration decision on its next-generation successor to Viekira Pak, and that successor is easier to dose than Viekira Pak, can be given over as few as eight weeks, and delivers high cure rates across genotypes.Those advantages could help stabilize AbbVie’s hepatitis C market share, which has declined in the past year.
- [By Keith Speights, Brian Stoffel, and George Budwell]
Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.
- [By Teresa Rivas]
AbbVie (ABBV) announced after the close of trading Wednesday that its experimental cancer treatment, the PARP-inhibitor veliparib, didnt meet the goals of late-stage studies.
The trials tested a combination of veliparib with chemotherapy against chemo alone, and the results showed that the drug didnt provide an added benefit.
Leerinks GeoffreyPorges reiterated a Market Perform rating and $71 price target on the stock today. From his note:
AbbVies PARP strategy was to test if its molecule could augment the benefit of chemotherapy, and while these data suggest there could be a lack of synergistic benefit with concomitant PARP therapy, a more likely explanation is that the inferior profile of veliparib compared to others in the PARP class undermined the drugs prospects to achieve this synergy. While two disappointing trials would not normally completely doom a program, the lack of effect indeed confirms our view that veliparib has limited activity and is not competitive with other products in this class. For this reason we are taking the probability of success (POS) of the program to zero, and reducing our revenue and earnings expectations accordingly; this amounts to a 1% change to medium- to long-term revenue, and a 1-2% impact on earnings. The failure of veliparib is unfortunate for ABBVs oncology strategy, which is grounded in complementary contributions from both internal discovery & external acquisitions, and is focused on both hematological & solid tumor malignancies. At this stage at least, the solid tumor outlook and ABBV’s internal contributions to the portfolio seem a bit more uncertain, leaving ABBV still likely looking for additional assets in solid tumor area to bolster that side of its portfolio.
He removed veliparib from his models, but writes that there are other promising drugs in AbbVies pipeline.
The market seems to agree, as AbbVie is up 0.8% to $63.96 in afternoon trad
what is an investment: CTI BioPharma Corp.(CTIC)
- [By Ashley Moore]
Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:
Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%
what is an investment: ZTE Corporation (ZTCOF)
- [By SEEKINGALPHA.COM]
Chinese telco equipment giant ZTE (OTCPK:ZTCOF) has been actively cooperating and communicating with relevant U.S. government departments in order to reach a conclusion of the investigation related to the compny’s violations of sanctions on Iran.
- [By SEEKINGALPHA.COM]
The United States has a history of preventing Chinese companies that are even suspected of being state-owned from selling certain products into key industries. Huawei and ZTE (OTCPK:ZTCOF), for example, were under harsh scrutiny for their telecommunications equipment.
what is an investment: AltaGas Ltd. (ATGFF)
- [By SEEKINGALPHA.COM]
AltaGas (OTCPK:ATGFF) recently announced that it’s going to acquire WGL Holdings (NYSE:WGL). This article will examine the financial side of the transaction. A number of Seeking Alpha authors have written articles on the merger as well, and I suggest that you read them.
- [By SEEKINGALPHA.COM]
Regulators in California are behind a new business of providing utility-scale back-up battery storage at power generating facilities. Canadian-based AltaGas (OTCPK:ATGFF) recently announced a 10-year Energy Storage Resource Adequacy Purchase Agreement with Southern California Edison SCE, a subsidiary of Edison International (NYSE:EIX). A recap of the scope of the contract is described below, from ATGFF’s press release:
what is an investment: Federal Agricultural Mortgage Corporation(AGM)
- [By Shanthi Rexaline]
Federal Agricultural Mortgage Corp. (NYSE: AGM): +233 percent since 2011.
Notwithstanding the drought, seed companies and agri-produce companies have fared well. The performance of pesticide and fertilizer companies were mixed during the period.
what is an investment: Sapiens International Corporation N.V.(SPNS)
- [By Lisa Levin] Gainers Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday. Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter. Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday. Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday. Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances. Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral. Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday. Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems. Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend. BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc. Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday. Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than